Deals Of The Week Ponders The ACA
Executive Summary
In a slow week for pharma deals, standouts included GSK’s wrap up with MorphoSys for a mid-stage rheumatoid arthritis drug, Pfizer’s deal to gain access to novel kinds of antibody drug-conjugates through platform company CytomX, and the first microbiome deal between a big pharma (Janssen) and a start-up, Second Genome.
You may also be interested in...
Elan’s Martin Aims To Set The Record Straight About Recent Buying Spree
Changes at the Irish company have sparked a swath of media speculation and analyst interest. Elan CEO Kelly Martin used a recent fireside chat in New York to paint a clearer picture of what is going on at the company and the rationale behind its recently proposed M&A.
Wall Street’s Take On Health Care Exchanges
Health care exchanges for expanding insurance coverage as part of the Affordable Care Act will open in time to meet the law’s January 1 deadline, but their “robustness” and ease of use, at least initially, may be questionable, a panel of experts tells Wall Street.
Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.